Recent events
Recent events tied to this brand in public sources.
Back to profile4 entries
2026
LEO Pharma acquires worldwide rights to dersimelagon from Tanabe Pharma
LEO Pharma agreed to acquire worldwide rights to dersimelagon, an oral once-daily MC1R agonist being developed for EPP and XLP, from Tanabe Pharma for up to $435m in up-front and near-term milestone payments plus potential downstream milestones and tiered royalties on net sales.
2022
LEO Pharma appoints Brian Hilberdink as U.S. president
LEO Pharma announced the appointment of Brian Hilberdink as Executive Vice President and President of LEO Pharma Inc. in the United States, effective March 14, 2022.
2022
Medable acquires Omhu
Medable announced that it had acquired Omhu A/S from LEO Innovation Lab's owner, LEO Pharma A/S, taking over Omhu's mobile applications and a team of 38 people.
2020
LEO Pharma appoints Nadege Feeser to lead its Atopic Dermatitis Business Unit
LEO Pharma UK and Ireland appointed Nadege Feeser to lead its Atopic Dermatitis Business Unit and drive its work in atopic dermatitis across northern European cluster countries.